MP2PRT: Identification of genetic changes associated with relapse and/or adaptive resistance in patients registered as Favorable Histology Wilms Tumor on AREN03B2
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA601251 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:MP2PRT: Identification of genetic changes associated with relapse and/or adaptive resistance in patients registered as Favorable Histology Wilms Tumor on AREN03B2
| PRJNA601250 | ENA
Project description:The gene expression patterns of favorable histology Wilms tumors (FHWT) that relapsed were compared with those that did not relapse using oligonucleotide arrays Description: 250 FHWT of all stages enriched for relapses treated on National Wilms Tumor Study 5 passed quality parameters and were suitable for analysis using oligonucleotide arrays. Relapse risk stratification utilized Support Vector Machine; two and ten fold cross-validation was applied. The number of genes associated with relapse was less than that predicted by chance alone for 106 patients (32 relapses) with stages I and II FHWT and no further analyses were performed. This number was greater than expected by chance for 76 local stage III patients. Cross validation including an additional 68 local stage III patients (total 144 patients, 53 relapses) demonstrated that classifiers for relapse composed of 50 genes were associated with a median sensitivity of 47%, specificity 70%, and total error rate of 38%. Analysis of genes differentially expressed in relapse patients revealed apoptosis, Wnt signaling, IGF pathway, and epigenetic modification to be mechanisms important in relapse. Potential therapeutic targets include FRAP/MTOR and CD40. Keywords: Classification by microarray analysis
2009-01-30 | GSE10320 | GEO
Project description:NCTN: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
| PRJNA1288589 | ENA
Project description:NCTN: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
| PRJNA1288590 | ENA
Project description:NCTN: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
| PRJNA1288587 | ENA
Project description:NCTN: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
| PRJNA1288588 | ENA
Project description:The gene expression patterns of favorable histology Wilms tumors (FHWT) that relapsed were compared with those that did not relapse using oligonucleotide arrays; Description: 250 FHWT of all stages enriched for relapses treated on National Wilms Tumor Study 5 passed quality parameters and were suitable for analysis using oligonucleotide arrays. Relapse risk stratification utilized Support Vector Machine; two and ten fold cross-validation was applied. The number of genes associated with relapse was less than that predicted by chance alone for 106 patients (32 relapses) with stages I and II FHWT and no further analyses were performed. This number was greater than expected by chance for 76 local stage III patients. Cross validation including an additional 68 local stage III patients (total 144 patients, 53 relapses) demonstrated that classifiers for relapse composed of 50 genes were associated with a median sensitivity of 47%, specificity 70%, and total error rate of 38%. Analysis of genes differentially expressed in relapse patients revealed apoptosis, Wnt signaling, IGF pathway, and epigenetic modification to be mechanisms important in relapse. Potential therapeutic targets include FRAP/MTOR and CD40. Experiment Overall Design: 144 stage 3 FHWT, with fifty-three relapses (cases) and ninety-one non-relapses (controls) with a minimum of three years follow-up, included all relapses and a 30% random selection of non-relapses for which frozen tumor tissue was available who passed all quality control parameters. The NWTS-5 protocol was approved by the review boards of institutions that registered patients. Histological diagnosis and local stage were confirmed by central review. Experiment Overall Design: Quality control steps taken: Experiment Overall Design: 1. Samples were snap frozen immediately following surgery and were mailed on dry ice to the Tumor Bank and retained at -80C. Experiment Overall Design: 2. Frozen sections were evaluated histologically and tumors with less than 80% viable tumor cellularity were excluded. Experiment Overall Design: 3. Array images were assessed by eye to confirm scanner alignment and the absence of significant bubbles or scratches. Experiment Overall Design: 4. Samples for which the 3'/5' ratios for GAPDH were greater than 3.2 were excluded. Experiment Overall Design: 5. The BioB spike controls were confirmed as present; BioC, BioD and cre were confirmed as increasing intensity. Experiment Overall Design: 6. When scaled to a target intensity of 2500, scaling factors were between 12 and 53; background levels were 34 â 115: Q values were 1.3 â 3.7 and mean intensities were within acceptable limits. Experiment Overall Design: 7. The range of percent present calls was from 38% to 52%. Experiment Overall Design: 8. Verification of gene expression was performed utilizing quantitative RT-PCR for five genes. Â Â Experiment Overall Design: Statistical Analysis: Positional-dependent-nearest-neighbor model (PDNN) software was used to translate the scanned images into expression analysis files and to normalize the data across all arrays (http://odin.mdacc.tmc.edu/~zhangli/PerfectMatch/). Genes with maximum expression less than a log scale of 6 across all tumors and Affymetrix control genes were excluded, resulting in 20,931 probe sets for analysis. Support Vector Machine (SVM) as developed by Chang and Lin (http://www.csie.ntu.edu.tw/~cjlin/libsvm) and implemented in an R software package, e1071 was chosen for relapse risk stratification using the p-value of the t-test comparison between case and control to select the genes. Using all 144 tumors, 109 genes were identified with p-value <0.001 and are provided in the data table labelled "t-test comparison between case and control" (ie, Supplemental table 2, in related publication)." Two and ten fold cross validations were utilized to investigate the ability of classifiers established in randomly selected training set to predict relapse in an independent test set comprised of the remaining tumors. For two-fold cross validation, the dataset was randomly divided 500 times into training and corresponding test sets of equal size, each including half the patients who relapsed. A classifier for relapse was identified for each training set and used to assign tumors in the corresponding test set to low and high risk categories. The training and test sets were then swapped. The number of top K genes in each classifier evaluated ranged from 1-150. Therefore, a total of 150,000 different classifiers were developed, one for each value of K from 1-150, for each of the 1,000 (500*2) training sets. For ten-fold cross validation the dataset was randomly divided 500 times into ten groups of approximately equal size. Each group included approximately the same number of relapses. For each such group, a classifier was built with the remaining 9/10 of the samples and then used to categorize tumors in the group as low or high risk; the process was repeated until all tumor samples were categorized as low or high risk. For all the cross validation procedures, to avoid gene-selection bias, classifiers were completely rebuilt in each cross validation iteration.
2009-02-09 | E-GEOD-10320 | biostudies-arrayexpress
Project description:Wilms tumor, or nephroblastoma, is the most common pediatric kidney cancer, and is known to arise from renal precursor cells in the fetal kidney. Given that single nuclei RNA-sequencing generates gene expression profiles of diverse cell types within a heterogeneous tissue, here we sought to utilize this technology to profile blastema, stroma, and epithelial components of favorable histology Wilms tumor samples.
2025-06-01 | GSE296618 | GEO
Project description:ABSTRACT Introduction and Objectives Wilms’ tumor (WT) relapse occurs in 15% of patients. We aim to investigate the association between the expression of several genetic markers and WT relapse risk. Materials and methods The study included 51 children treated for WT at a tertiary center between 2001 and 2019: 23 patients had disease relapse (group A) and 28 remained relapse-free after at least 2 years of follow-up (group B). Patients with syndromic, bilateral synchronous or anaplastic WT were excluded. Autologous renal tissue from 20 patients served as control. Total RNA was isolated from tumor tissue and control. Gene expression levels of WT1, HIF1α, b-FGF, c-MYC and SLC22A18 were assessed using quantitative RT-PCR and normalized to GAPDH. Immunohistochemical staining for WT1 and gene expression levels were compared between the study groups. Results Median patient age was 3 (IQR = 2–5) years and 36 (70.6%) had stage I disease. Baseline characteristics were similar between study groups. Relapse occurred at a median of 6.8 (2.8–24.7) months, predominantly in the lungs (11/23, 47.8%). Tumors that relapsed expressed significantly higher levels of WT1, HIF1α, b-FGF and c-MYC and lower levels of SLC22A18 (p < 0.001). Strong immunohistochemical staining for WT1 was seen in 73.9% of group A and 14.29% of group B (p < 0.001). These associations retained statistical significance irrespective of patient and tumor characteristics. Conclusions Higher expression levels of WT1, HIF1 α, b-FGF and c-MYC and lower level of SLC22A18 are associated with increased risk of WT relapse. These genetic markers can serve as future prognostic predictors and help stratify patients for treatment.
| S-EPMC9930804 | biostudies-literature
Project description:Purpose: The 10x Genomics Visium platform allows us to define the spatial topography of gene expression and provides detailed molecular maps that overcome limitations associated with sn/scRNA-seq and microscopy-based spatial transcriptomics methods. The goals of this study are to compare and identify unique transcriptome profiling (RNA-seq) signature between unfavorable and favorable Wilms Tumors and against human fetal kidney. Methods: Human fetal kidney and Wilms tumor spatial topography of gene expression were generated using the 10X Visium platform Results: Using an optimized data analysis workflow, we mapped the reads to the hg38 genome build and grouped the spots into 9 clusters based on gene expression profiles. Conclusion: Our study represents the first implement of Visium technology in human fetal kidney and Wilms Tumor tissue, providing a number of important functional insights about the spatial and molecular definitions of cell populations across human fetal kidney and different subtypes of Wilms Tumor through analyzing gene expression within the intact spatial organization of the human samples.
2023-07-01 | GSE178349 | GEO